{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:27:57Z","timestamp":1788280077438,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ccl.2021.08.005","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T19:33:01Z","timestamp":1637350381000},"page":"77-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lung Disease\u2013Related Pulmonary Hypertension"],"prefix":"10.1016","volume":"40","author":[{"given":"Kareem","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikramjit","family":"Khangoora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccl.2021.08.005_bib1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.27.4.594","article-title":"Chronic cor pulmonale: report of an expert committee. WHO Technical Report Series No. 213","volume":"27","author":"Dankmeijer","year":"1963","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.ccl.2021.08.005_bib2","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1161\/CIRCULATIONAHA.106.685206","article-title":"Pulmonary diseases and the heart","volume":"116","author":"Han","year":"2007","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.ccl.2021.08.005_bib3","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1513\/AnnalsATS.201710-772KV","article-title":"Cor pulmonale revisited. From Ferrer and Harvey to the present","volume":"15","author":"Rubin","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.ccl.2021.08.005_bib4","doi-asserted-by":"crossref","first-page":"1801914","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ccl.2021.08.005_bib5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4081\/monaldi.2004.693","article-title":"Pulmonary haemodynamics in patients with OSAS or an overlap syndrome","volume":"61","author":"Hawrylkiewicz","year":"2004","journal-title":"Monaldi Arch Chest Dis"},{"key":"10.1016\/j.ccl.2021.08.005_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.resp.2019.01.003","article-title":"Borderline pulmonary hypertension associated with chronic hypercapnia in chronic pulmonary disease","volume":"262","author":"Zuoyou","year":"2019","journal-title":"Respir Physiol Neurobiol"},{"issue":"3","key":"10.1016\/j.ccl.2021.08.005_bib7","first-page":"413","article-title":"Group III pulmonary hypertension: pulmonary hypertension associated with lung disease\u2014epidemiology, pathophysiology, and treatments","volume":"34","author":"Klinger","year":"2016","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.ccl.2021.08.005_bib8","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1172\/JCI33338","article-title":"Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration","volume":"119","author":"Zhao","year":"2009","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.ccl.2021.08.005_bib9","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1183\/09031936.97.10092055","article-title":"Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease. Relation with pulmonary hypertension during exercise","volume":"10","author":"Yamakami","year":"1997","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ccl.2021.08.005_bib10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1165\/ajrcmb.16.2.9032126","article-title":"Elevated expression of endothelin-1 and endothelin converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines","volume":"16","author":"Saleh","year":"1997","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"10.1016\/j.ccl.2021.08.005_bib11","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1152\/jappl.1991.71.6.2218","article-title":"Polycythemia and vascular remodeling in chronic hypoxic pulmonary hypertension in Guinea pigs","volume":"71","author":"Janssens","year":"1991","journal-title":"J\u00a0Appl Physiol (1985)"},{"issue":"1","key":"10.1016\/j.ccl.2021.08.005_bib12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09031936.00147712","article-title":"Functional impact of pulmonary hypertension due to hypoventilation and changes under noninvasive ventilation","volume":"43","author":"Held","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccl.2021.08.005_bib13","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1161\/01.CIR.0000091409.53101.E8","article-title":"Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary diseases","volume":"108","author":"Eddahibi","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccl.2021.08.005_bib14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1378\/chest.06-2485","article-title":"Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis","volume":"131","author":"Nathan","year":"2007","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ccl.2021.08.005_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.healun.2018.09.011","article-title":"Survival in pulmonary hypertension due to chronic lung disease: influence of low diffusion capacity of the lungs for carbon monoxide","volume":"38","author":"Rose","year":"2019","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"3","key":"10.1016\/j.ccl.2021.08.005_bib16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1440-1843.2010.01877.x","article-title":"Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis","volume":"16","author":"Swigris","year":"2011","journal-title":"Respirology"},{"issue":"7","key":"10.1016\/j.ccl.2021.08.005_bib17","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/resp.13066","article-title":"CT-determined pulmonary artery to aorta ratio as a predictor of elevated pulmonary artery pressure and survival in idiopathic pulmonary fibrosis","volume":"22","author":"Yagi","year":"2017","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.ccl.2021.08.005_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.chest.2019.06.033","article-title":"Right ventricular to left ventricular ratio at CT pulmonary angiogram predicts mortality in interstitial lung disease","volume":"157","author":"Bax","year":"2020","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.ccl.2021.08.005_bib19","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1164\/rccm.200510-1545OC","article-title":"Brain natriuretic peptide is a prognostic parameter in chronic lung disease","volume":"173","author":"Leuchte","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ccl.2021.08.005_bib20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1164\/rccm.200210-1130OC","article-title":"Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease","volume":"167","author":"Arcasoy","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccl.2021.08.005_bib21","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/crj.12608","article-title":"Pulmonary hypertension in advanced lung diseases: echocardiography as an important part of patient evaluation for lung transplantation","volume":"12","author":"Nowak","year":"2018","journal-title":"Clin Respir J"},{"key":"10.1016\/j.ccl.2021.08.005_bib22","doi-asserted-by":"crossref","first-page":"e011464","DOI":"10.1161\/JAHA.118.011464","article-title":"Clinical determinants and prognostic implications of right ventricular dysfunction in pulmonary hypertension caused by chronic lung disease","volume":"8","author":"Prins","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.ccl.2021.08.005_bib23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/CIRCIMAGING.113.000640","article-title":"Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension","volume":"6","author":"Fine","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.ccl.2021.08.005_bib24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.rmed.2019.03.004","article-title":"Outcomes of lung disease-associated pulmonary hypertension and impact of elevated pulmonary vascular resistance","volume":"150","author":"Awerbach","year":"2019","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.ccl.2021.08.005_bib25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/crj.12604","article-title":"Clinical and hemodynamic characteristics of pulmonary hypertension associated with interstitial lung disease in China","volume":"12","author":"Wang","year":"2018","journal-title":"Clin Respir J"},{"issue":"3","key":"10.1016\/j.ccl.2021.08.005_bib26","doi-asserted-by":"crossref","first-page":"1801015","DOI":"10.1183\/13993003.01015-2018","article-title":"Exercise pulmonary haemodynamic response predicts outcomes in fibrotic lung disease","volume":"52","author":"Jose","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccl.2021.08.005_bib27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1513\/pats.200708-124ET","article-title":"Oxygen therapy in chronic obstructive pulmonary disease","volume":"5","author":"Kim","year":"2008","journal-title":"Proc Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.ccl.2021.08.005_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018765835","article-title":"Prophylactic function of excellent compliance with LTOT in the development of pulmonary hypertension due to COPD with hypoxemia","volume":"8","author":"Xiong","year":"2018","journal-title":"Pulm Circ"},{"key":"10.1016\/j.ccl.2021.08.005_bib29","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/thx.2005.042994","article-title":"Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment","volume":"60","author":"Wright","year":"2005","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.ccl.2021.08.005_bib30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/jpet.108.148742","article-title":"Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats","volume":"330","author":"Izikki","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.ccl.2021.08.005_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/ejcts\/ezy092","article-title":"Lung volume reduction surgery in selected patients with emphysema and pulmonary hypertension","author":"Caviezel","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.ccl.2021.08.005_bib32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1164\/rccm.200608-1114OC","article-title":"Effect of lung volume reduction surgery on resting pulmonary hemodynamics in severe emphysema","volume":"176","author":"Criner","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccl.2021.08.005_bib33","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1164\/rccm.200608-1153CC","article-title":"Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots","volume":"175","author":"Nathan","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.ccl.2021.08.005_bib34","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1164\/rccm.201903-0488OC","article-title":"Nintedanib and sildenafil in patients with idiopathic pulmonary fibrosis and right heart dysfunction. A prespecified subgroup Analysis of a double-blind randomized clinical trial (INSTAGE)","volume":"200","author":"Behr","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccl.2021.08.005_bib35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2213-2600(20)30356-8","article-title":"Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.ccl.2021.08.005_bib36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4103\/2045-8932.94842","article-title":"Severe pulmonary hypertension in idiopathic nonspecific interstitial pneumonia","volume":"2","author":"Hallowell","year":"2012","journal-title":"Pulm Circ"},{"issue":"3","key":"10.1016\/j.ccl.2021.08.005_bib37","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00408-011-9361-9","article-title":"Pulmonary hypertension in chronic hypersensitivity pneumonitis","volume":"190","author":"Koschel","year":"2012","journal-title":"Lung"},{"issue":"2","key":"10.1016\/j.ccl.2021.08.005_bib38","first-page":"81","article-title":"Sildenafil improves six-minute walk distance in chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial","volume":"53","author":"Rao","year":"2011","journal-title":"Indian J Chest Dis Allied Sci"},{"issue":"4","key":"10.1016\/j.ccl.2021.08.005_bib39","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1183\/09031936.00176312","article-title":"Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial","volume":"42","author":"Blanco","year":"2013","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ccl.2021.08.005_bib40","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.healun.2016.04.010","article-title":"Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: a randomized controlled multicenter clinical trial","volume":"36","author":"Vitulo","year":"2017","journal-title":"J\u00a0Heart Lung Transpl"},{"issue":"3","key":"10.1016\/j.ccl.2021.08.005_bib41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/15412555.2011.651180","article-title":"Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial","volume":"9","author":"Lederer","year":"2012","journal-title":"COPD"},{"issue":"4","key":"10.1016\/j.ccl.2021.08.005_bib42","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S2213-2600(14)70013-X","article-title":"Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial","volume":"2","author":"Goudie","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.ccl.2021.08.005_bib43","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1002110","article-title":"A\u00a0controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis","volume":"363","author":"Zisman","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ccl.2021.08.005_bib44","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1378\/chest.12-1594","article-title":"Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction","volume":"143","author":"Han","year":"2013","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.ccl.2021.08.005_bib45","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.ccl.2021.08.005_bib46","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/680214","article-title":"Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease","volume":"5","author":"Ghofrani","year":"2015","journal-title":"Pulm Circ"},{"issue":"6","key":"10.1016\/j.ccl.2021.08.005_bib47","doi-asserted-by":"crossref","first-page":"1802445","DOI":"10.1183\/13993003.02445-2018","article-title":"Riociguat for treatment of pulmonary hypertension in COPD: a translational study","volume":"53","author":"Pichl","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccl.2021.08.005_bib48","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/07853890410018925","article-title":"Role of endothelin in fibrosis and anti-fibrotic potential of bosentan","volume":"37","author":"Clozel","year":"2005","journal-title":"Ann Med"},{"issue":"9","key":"10.1016\/j.ccl.2021.08.005_bib49","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","article-title":"Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial","volume":"158","author":"Raghu","year":"2013","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.ccl.2021.08.005_bib50","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1164\/rccm.201403-0446OC","article-title":"Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia","volume":"190","author":"Corte","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccl.2021.08.005_bib51","doi-asserted-by":"crossref","first-page":"1701857","DOI":"10.1183\/13993003.01857-2017","article-title":"Macitentan reduces progression of TGF-\u03b21-induced pulmonary fibrosis and pulmonary hypertension","volume":"52","author":"Bellaye","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccl.2021.08.005_bib52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1753465808103499","article-title":"Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease","volume":"3","author":"Valerio","year":"2009","journal-title":"Ther Adv Respir Dis"},{"issue":"3","key":"10.1016\/j.ccl.2021.08.005_bib53","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1183\/09031936.00011308","article-title":"A\u00a0randomised, controlled trial of bosentan in severe COPD","volume":"32","author":"Stolz","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccl.2021.08.005_bib54","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.2147\/COPD.S141798","article-title":"Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension","volume":"12","author":"Wang","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ccl.2021.08.005_bib55","doi-asserted-by":"crossref","first-page":"106354","DOI":"10.1016\/j.rmed.2021.106354","article-title":"Acute effect of inhaled iloprost on exercise dynamic hyperinflation in COPD patients: a randomized crossover study","volume":"180","author":"Lammi","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.ccl.2021.08.005_bib56","doi-asserted-by":"crossref","first-page":"633S","DOI":"10.1378\/chest.132.4_MeetingAbstracts.633a","article-title":"A\u00a0randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of iloprost inhalation in adults with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary fibrosis","volume":"132","author":"Krowka","year":"2007","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ccl.2021.08.005_bib57","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccl.2021.08.005_bib58","first-page":"S45","article-title":"Role of selexipag in COPD patients with out of proportion pulmonary hypertension","volume":"25","author":"Abuserewa","year":"2019","journal-title":"J\u00a0Card Fail"},{"issue":"2","key":"10.1016\/j.ccl.2021.08.005_bib59","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/ajrccm.160.2.9810008","article-title":"Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis","volume":"160","author":"Olschewski","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"20","key":"10.1016\/j.ccl.2021.08.005_bib60","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.2169\/internalmedicine.50.5995","article-title":"Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension","volume":"50","author":"Shimizu","year":"2011","journal-title":"Intern Med"},{"issue":"3 Pt 1","key":"10.1016\/j.ccl.2021.08.005_bib61","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.156.3.9611051","article-title":"Nitric oxide inhalation during exercise in chronic obstructive pulmonary disease","volume":"156","author":"Roger","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccl.2021.08.005_bib62","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/thorax.58.4.289","article-title":"Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD","volume":"58","author":"Vonbank","year":"2003","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.ccl.2021.08.005_bib63","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.chest.2020.02.016","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of pulsed, inhaled nitric oxide in subjects at risk of pulmonary hypertension associated with pulmonary fibrosis","volume":"158","author":"Nathan","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.ccl.2021.08.005_bib64","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.rmed.2017.04.010","article-title":"Adverse outcomes associated with pulmonary hypertension in chronic obstructive pulmonary disease after bilateral lung transplantation","volume":"128","author":"Hayes","year":"2017","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.ccl.2021.08.005_bib65","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/ctr.12692","article-title":"Pulmonary hypertension as a risk factor of mortality after lung transplantation","volume":"30","author":"Andersen","year":"2016","journal-title":"Clin Transpl"},{"issue":"3","key":"10.1016\/j.ccl.2021.08.005_bib66","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.21037\/jtd.2018.03.46","article-title":"Prognostic value of pre-transplant mean pulmonary arterial pressure in lung transplant recipients: a single-institution experience","volume":"10","author":"Kim","year":"2018","journal-title":"J\u00a0Thorac Dis"},{"issue":"10","key":"10.1016\/j.ccl.2021.08.005_bib67","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1513\/AnnalsATS.201610-810OC","article-title":"Clinical risk factors and prognostic model for primary graft dysfunction after lung transplantation in patients with pulmonary hypertension","volume":"14","author":"Porteous","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.ccl.2021.08.005_bib68","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.athoracsur.2018.04.068","article-title":"Increasing opportunity for lung transplant in interstitial lung disease with pulmonary hypertension","volume":"106","author":"Chicotka","year":"2018","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"10.1016\/j.ccl.2021.08.005_bib69","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/1089253219896123","article-title":"Extracorporeal membrane oxygenation in the perioperative care of the lung transplant patient","volume":"24","author":"Hayanga","year":"2020","journal-title":"Semin Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.ccl.2021.08.005_bib70","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/icvts\/ivx418","article-title":"Postoperative left ventricular function in different types of pulmonary hypertension: a comparative study","volume":"26","author":"Verbelen","year":"2018","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"9","key":"10.1016\/j.ccl.2021.08.005_bib71","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1177\/0269216313493467","article-title":"Palliative care for people with non-malignant lung disease: summary of current evidence and future direction","volume":"27","author":"Boland","year":"2013","journal-title":"Palliat Med"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865121000680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865121000680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:52:36Z","timestamp":1760007156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865121000680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0733865121000680"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2021.08.005","relation":{},"ISSN":["0733-8651"],"issn-type":[{"value":"0733-8651","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lung Disease\u2013Related Pulmonary Hypertension","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2021.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}